Sugi Predict

Sugi Predict / Compounds / SCHEMBL793762

SCHEMBL793762

SCHEMBL793762

Cc1c(Cl)cccc1S(=O)(=O)Nc1cccc(-c2nnn[nH]2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PFKFB3 Q16875 6/20 0.47
▸ HSD11B1 P28845 3/20 0.46
▸ EDNRB P24530 2/20 0.45
▸ EDNRA P25101 2/20 0.45
▸ LMNA P02545 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ SLC40A1 Q9NP59 1/20 0.42
▸ LNPEP Q9UIQ6 1/20 0.42
▸ WDR5 P61964 1/20 0.42
▸ GSPT1 P15170 1/20 0.41
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CCR4 P51679 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL793853 0.89 PFKFB3 (0.49) PFKFB3LMNATP53MAPTTHRB
SCHEMBL793409 0.89 PFKFB3 (0.55) PFKFB3LMNATHRBLNPEPKMT2A
SCHEMBL793550 0.87 MAPT (0.56) PFKFB3LMNATP53MAPTTHRB
SCHEMBL792880 0.86 PFKFB3 (0.54) PFKFB3LMNATP53MAPTTHRB
SCHEMBL794311 0.85 PFKFB3 (0.65) PFKFB3LMNATP53MAPTTHRB
SCHEMBL794260 0.83 PFKFB3 (0.53) PFKFB3LMNAMAPTSLC40A1LNPEP
SCHEMBL793555 0.83 PFKFB3 (0.66) PFKFB3LMNATP53MAPTTHRB
SCHEMBL793284 0.83 ALDH1A1 (0.52) PFKFB3HSD11B1MAPTLNPEPKMT2A
SCHEMBL792988 0.81 PFKFB4 (0.58) PFKFB3LNPEP
SCHEMBL793856 0.81 PFKFB3 (0.67) PFKFB3LMNATP53MAPTLNPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616450-A2 SULFONAMIDE COMPOUNDS Kancera AB (SE) 2013-07-24 — — EP claimed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 — — US claimed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 — — WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 — — US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 — — CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 — — WO disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 — — US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 — — US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 — — US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885HSD11B1 3326/4885EDNRB 3129/4885
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA PFKFB3 952/4885HSD11B1 2773/4885EDNRB 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.